Opinion|Videos|May 29, 2024
High Oral Corticosteroid Dose and Exposure in Asthma
The panel addresses the issue of patients being exposed to high levels of oral corticosteroids (OCS) without realizing it, as various prescribers can administer steroids. They also discuss the essential questions healthcare professionals should ask to comprehend a patient's total OCS exposure and provide a definition of high OCS use.
Advertisement
Episodes in this series
Advertisement
Related to this article
Clinicians described how steroid exposure from multiple prescribers shapes biologic decisions in asthma and COPD.
APPs described earlier recognition of type 2 disease, documentation strategies for payers, and the role of specialty pharmacy in biologic access.
Check out highlights from news published on day 1 of CHEST 2026, spanning asthma, COPD, bronchiectasis, pulmonary rehabilitation, and fibrotic ILD.
Chronic proton pump inhibitor use carried 60% greater odds of asthma exacerbation and nearly 4-fold odds of rescue corticosteroid use in a matched cohort of 2456 patients.
Advertisement
Advertisement
Trending on HCPLive
1
Tozorakimab Improves Daily Respiratory Symptoms in COPD: OBERON, TITANIA
2
Tozorakimab Sustains COPD Exacerbation Benefit to 2 Years: Henrik Watz, MD
3
AAD's New HS Guidelines Flag 'Step Therapy' as Top Barrier to Care
4
Depemokimab Year 1 Remission Linked to Better Year 2 Asthma Outcomes
5